Patents by Inventor Yi Zhu

Yi Zhu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treating pulmonary conditions by selectively removing senescent cells from the lung using an intermittent dosing regimen
    Patent number: 10258618
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: April 16, 2019
    Assignees: UNITY BIOTECHNOLOGY, INC., BUCK INSTITUTE FOR RESEARCH AGING, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Darren J. Baker, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Jan M. A. van Deursen
  • Hop-aware multicast in a mesh network
    Patent number: 10257077
    Abstract: A mesh network device includes a radio and an application processor including a hop-aware multicast engine to: determine a mesh header time to live (TTL) value for a broadcast frame in a data link layer. The mesh header TTL value is the lessor of an internet protocol (IP) header TTL value of the first broadcast frame in an IP layer and a predefined value. The broadcast frame includes a request for a service or a resource to be sent. The hop-aware multicast engine sends the broadcast frame to a first set of mesh network devices being defined by the mesh header TTL value. The hop-aware multi-case engine determines that a response was not received within a time period; increases the mesh header TTL value; and sends a broadcast frame to a second set of one or more additional mesh network devices being defined by the increased mesh header TTL value.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: April 9, 2019
    Assignee: Amazon Technologies, Inc.
    Inventors: Yi Zhu, Varadarajan Gopalakrishnan, Kiran Kumar Edara, Sheung Mei Chan
  • ROLES OF MODULATORS OF INTERSECTIN-CDC42 SIGNALING IN ALZHEIMER'S DISEASE
    Publication number: 20190091184
    Abstract: Methods of treating Alzheimer's disease and other neurodegenerative and/or neurocognitive and/or neurodevelopmental diseases are described. The methods comprise the administration of compounds that modulate an activity of cell division control protein 42 (Cdc42), such as the interaction between Cdc42 and intersectin (ITSN). Exemplary modulator compounds include thioureas, disulfonamides of fused aromatic systems (e.g., benzofuran), and acyl hydrazones, among others. Some of the modulator compounds act as activators of Cdc42, while others act as inhibitors. In some cases, the modulator compound has dual functionality and the ability of the modulator compound to act as an inhibitor or activator depends on whether or not Cdc42 is already activated in a particular disease stage or biological environment by an upstream activating signal of Cdc42.
    Type: Application
    Filed: September 25, 2018
    Publication date: March 28, 2019
    Inventors: Qun Lu, Byron Aguilar, Yi Zhu, Yan-Hua Chen
  • Software interface layer of a mesh network device
    Patent number: 10230636
    Abstract: Network hardware devices organized in a wireless mesh network (WMN) in which one network hardware devices includes a first radio and a second radio coupled to a processing device. The processing device receives a request from a client consumption device via the first radio and determines a destination for the request as a second mesh network device. The processing device access a master routing table to determine that the second radio is to forward the request and forwards the request to the second radio. The second radio accesses a local routing table at the second radio to determine that a radio of a third mesh network device is a next-hop mesh network device in a first path to the second mesh network device. The second radio sends the request to the radio of the third mesh network device.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: March 12, 2019
    Assignee: Amazon Technologies, Inc.
    Inventors: Sheung Mei Chan, Andrew David Price, Varadarajan Gopalakrishnan, Yi Zhu, Lori Yoshida
  • Method of optimizing conditions for selectively removing a plurality of senescent cells from a tissue or a mixed cell population
    Patent number: 10213426
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: February 26, 2019
    Assignees: UNITY BIOTECHNOLOGY, INC., BUCK INSTITUE FOR RESEARCH ON AGING, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Yi Zhu, James L. Kirkland, Tamar Tchkonia
  • USE OF SULFONAMIDE INHIBITORS OF BCL-2 AND BCL-XL TO TREAT OPHTHALMIC DISEASE BY SELECTIVELY REMOVING SENESCENT CELLS
    Publication number: 20190022090
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Application
    Filed: August 3, 2018
    Publication date: January 24, 2019
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Darren J. Baker, Bennett G. Childs, Jan M.A. van Deursen
  • GUARD BOND WIRES IN AN INTEGRATED CIRCUIT PACKAGE
    Publication number: 20190006286
    Abstract: An integrated circuit package is provided. The integrated circuit package comprises a first and second guard bond wire. The first guard bond wire has a first and second end coupled to ground. The second guard bond wire has a first and second end coupled to ground. The integrated circuit package further comprises a die. The die is mounted between the first and second guard bond wires such that the first and second guard bond wires distort a magnetic field between at least an input terminal and an output terminal of the die.
    Type: Application
    Filed: May 12, 2016
    Publication date: January 3, 2019
    Inventors: Vittorio CUOCO, Youri VOLKHINE, Yi ZHU, Josephus VAN DER ZANDEN, Anna WALESIENIUK
  • Pharmaceutical Products and Drug Combinations for Treating Atherosclerosis by Stabilizing Atherosclerotic Plaques and Promoting Plaque Regression
    Publication number: 20190000846
    Abstract: Foamy macrophages with senescence markers accumulate in the subendothelial space at the onset of atherosclerosis where they drive pathology by increasing expression of key atherogenic and inflammatory cytokines and chemokines. This invention provides senolytic agents that remove senescent cells that are present in or around atherosclerotic plaques. The agents inhibit or reverse thinning of the fibrous cap on atherosclerotic plaques. This has the effect of stabilizing the plaques, inhibiting rupture and preventing pathological sequelae that manifest as coronary artery disease. Senolytic agents used in this way complement the action of statins and other drugs that cause plaque regression. Thus, senolytic agents and lipid lowering drugs can be used in combination for enhanced therapeutic effect.
    Type: Application
    Filed: July 2, 2018
    Publication date: January 3, 2019
    Inventors: Jan M.A. van Deursen, Bennett G. Childs, Darren J. Baker, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Nathaniel David, Remi-Martin Laberge, Judith Campisi, Marco Demaria
  • Treatment of joint pain
    Patent number: 10130628
    Abstract: This disclosure provides a technology for managing the sensation of pain in a subject in need thereof. Treatment methods according to this invention include administering to the subject a formulation that contains an effective amount of (4-[(4S,5R)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-piperazinone).
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: November 20, 2018
    Assignees: UNITY BIOTECHNOLOGY, INC., BUCK INSTITUTE FOR RESEARCH ON AGING, THE JOHNS HOPKINS UNIVERSITY, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Nathaniel David, Albert Davalos, Remi-Martin Laberge, Judith Campisi, Marco Demaria, Alain Vasserot, Chaekyu Kim, Okhee Jeon, Jennifer Elisseeff, James L. Kirkland, Tamar Tchkonia, Yi Zhu
  • Neighbor discovery and neighbor selection of mesh network devices in a mesh network
    Patent number: 10129731
    Abstract: Network hardware devices organized in a wireless mesh network (WMN) in which one network hardware devices includes multiple radios. A processing device of a first network hardware device scans a channel of the first radio for access point (AP) beacon frames that each contains information identifying a mesh network device in a WMN. The processing device creates a list of a plurality of mesh network device from the AP beacon frames and transmits a location probe transmission by each of the plurality of radios one sector at a time in a neighbor discovery process. The processing device receives metrics of the location probe transmissions received by the plurality of mesh network devices in the neighbor discovery process and configures each of the plurality of radios to communicate with one of a set of neighbor mesh network devices using the metrics in a neighbor selection process.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: November 13, 2018
    Assignee: Amazon Technologies, Inc.
    Inventors: Lori Yoshida, Andrew David Price, Varadaranjan Gopalakrishnan, Yi Zhu, Sheung Mei Chan
  • Unit Dose of an MDM2 Inhibitor that Provides Long-Lasting Relief from Idiopathic Pulmonary Fibrosis and other Pulmonary Conditions by Selectively Removing Senescent Cells from the Lung
    Publication number: 20180303828
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Application
    Filed: June 13, 2018
    Publication date: October 25, 2018
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Darren J. Baker, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Jan M.A. van Deursen
  • Methods and Compositions for Killing Senescent Cells and for Treating Senescence-Associated Diseases and Disorders
    Publication number: 20180256568
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Application
    Filed: April 11, 2018
    Publication date: September 13, 2018
    Inventors: Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, Darren J. Baker, Bennett G. Childs, James L. Kirkland, Tamar Tchkonia, Jan M.A. van Deursen, Jennifer Elisseeff, Chaekyu Kim, Okhee Jeon, Allyson K. Palmer, Yi Zhu
  • REMOVING SENESCENT CELLS FROM A MIXED CELL POPULATION OR TISSUE USING A PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITOR
    Publication number: 20180250296
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Application
    Filed: May 16, 2018
    Publication date: September 6, 2018
    Inventors: Remi-Martin Laberge, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Nathaniel David, Alain Philippe Vasserot, Darren J. Baker, Bennett G. Childs, Jan M.A. van Deursen
  • Treatment of Ophthalmic Conditions by Selectively Removing Senescent Cells from the Eye
    Publication number: 20180235957
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Application
    Filed: April 18, 2018
    Publication date: August 23, 2018
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Darren J. Baker, Bennett G. Childs, Jan M.A. van Deursen
  • TREATING PULMONARY CONDITIONS BY SELECTIVELY REMOVING SENESCENT CELLS FROM THE LUNG USING AN INTERMITTENT DOSING REGIMEN
    Publication number: 20180235956
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Application
    Filed: April 17, 2018
    Publication date: August 23, 2018
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Darren J. Baker, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Jan M.A. van Deursen
  • COMPOSITIONS AND METHODS FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS
    Publication number: 20180193458
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders. Also included herein are methods for extending lifespan.
    Type: Application
    Filed: July 8, 2016
    Publication date: July 12, 2018
    Inventors: Jose Alberto Lopez-Dominguez, Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, Darren J. Baker, Bennett G. Childs, James L. Kirkland, Tamar Tchkonia, Jan M.A. van Deursen, Yi Zhu
  • Treatment of ophthalmic conditions by selectively removing senescent cells from the eye
    Patent number: 10010546
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: July 3, 2018
    Assignees: Unity Biotechnology, Inc., Buck Institute for Research on Aging, Mayo Foundation for Medical Education and Research
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Darren J. Baker, Bennett G. Childs, Jan M. A. van Deursen
  • Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
    Patent number: 9993472
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: June 12, 2018
    Assignees: UNITY BIOTECHNOLOGY, INC., BUCK INSTITUTE FOR RESEARCH ON AGING, THE JOHN HOPKINS UNIVERSITY, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Jan M. A. van Deursen, Jennifer Elisseeff, Chaekyu Kim, Okhee Jeon, Yi Zhu
  • Use of sulfonamide inhibitors of Bcl-2 to treat senescence-associated lung conditions such as pulmonary fibrosis and chronic obstructive pulmonary disease
    Patent number: 9980962
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: May 29, 2018
    Assignees: UNITY BIOTECHNOLOGY, INC, BUCK INSTITUTE FOR RESEARCH ON AGING, MAYO FOUNDATION FOR MEDICAL EDUCATIOIN AND RESEARCH
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Darren J. Baker, James L. Kirkland, Tamar Tchkonia, Jan M. A. van Deursen, Yi Zhu
  • TREATMENT OF OPHTHALMIC CONDITIONS BY SELECTIVELY REMOVING SENESCENT CELLS FROM THE EYE
    Publication number: 20180117038
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Application
    Filed: November 30, 2017
    Publication date: May 3, 2018
    Inventors: Remi-Martin Laberge, Judith Campisi, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Yi Zhu